602 results on '"Diehn, M."'
Search Results
2. A Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery (SRS) for Large Resection Cavities of Brain Metastases
3. Prospective Trial of Using Imaging to Predict Pathologic Response and Clinical Outcomes in Locally Advanced Esophageal Cancer
4. Hyperfractionated Reirradiation for Locally Recurrent Thoracic Tumors
5. Predicting Local Control with Dosimetric Parameters in Patients Receiving Individualized Stereotactic Ablative Radiotherapy for Lung Tumors
6. Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLC
7. Investigating Dosimetry and Imaging Biomarkers for Prediction of Major Adverse Cardiac Events Following Locally Advanced Non-Small Cell Lung Cancer Radiotherapy
8. COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCL
9. FOLLICULAR LYMPHOMA PATIENT‐DERIVED ORGANOIDS FOR BISPECIFIC T‐CELL ENGAGER IMMUNOTHERAPY
10. P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC.
11. Investigating the Impact of Coronary Artery Dosimetry on Major Adverse Cardiac Events after Thoracic Radiation Therapy
12. Characterizing Metastatic Non-Small Cell Lung Cancer Presenting to an Academic Medical Center in an Era of Changing Treatment Paradigms
13. OA14.04 Chest Wall Toxicity after Individualized Stereotactic Ablative Radiotherapy for Lung Tumors
14. EP.04E.02 Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis
15. A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
16. Association between Inter-Fraction Tumor Volume Changes and Patient Outcomes from Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer
17. Predictors of Atrial Fibrillation after Thoracic Radiotherapy
18. Local Control by Motion Management Strategy of Thoracic Tumors: Secondary Analysis of the iSABR Trial
19. 293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
20. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
21. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
22. Deep Learning Based Identification and Segmentation of Lung Tumors on Computed Tomography Images
23. Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
24. Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC)
25. Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
26. A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
27. MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS.
28. DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA
29. PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY
30. CLONAL HEMATOPOIESIS IS ASSOCIATED WITH INFERIOR PROGNOSIS IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS
31. NONINVASIVE DETECTION, CLASSIFICATION, AND RISK STRATIFICATION OF PRIMARY CNS LYMPHOMAS BY CTDNA PROFILING
32. MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE‐BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7‐YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIAL
33. An antibiotic-resistance conferring mutation in a neisserial porin: Structure, ion flux, and ampicillin binding
34. MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
35. An antibiotic-resistance conferring mutation in a neisserial porin: Structure, ion flux, and ampicillin binding
36. Cardiac Toxicities and Outcomes Following Stereotactic Ablative Radiation to Thoracic Cancers
37. Pre-Treatment Lung FDG-PET Uptake is Correlated with Radiologic Lung Fibrosis after Stereotactic Ablative Radiotherapy (SABR)
38. Parametric Response Mapping as an Imaging Biomarker for Regional Ventilation in Stereotactic Ablative Radiotherapy
39. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
40. Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE)
41. P2.05-01 Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
42. Investigating and Validating Metabolic Tumor Volume As a Prognostic Factor for Local Recurrence in Early Stage Lung Cancer
43. Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes
44. Outcomes of Oligometastatic Colorectal Cancer treated with Stereotactic Ablative Radiotherapy
45. Symptomatic Cardiac Events in Patients with Lung Tumors Near The Heart Treated with Stereotactic Ablative Radiotherapy (SABR): A Single Institution Experience
46. Influence of Dose and Fractionation on Radiologic Lung Fibrosis after Stereotactic Ablative Radiotherapy (SABR)
47. Molecular Profiling of Oligometastases and Artificial Intelligence-based Model for Predicting Treatment Outcome in Advance Prostate Cancer
48. Esophagitis in Patients Treated with Thoracic Stereotactic Ablative Radiation Therapy (SABR) to Tumors within 2 cm of the Esophagus
49. Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer
50. Pulmonary Interstitial Lymphography and Patterns of Recurrence after Stereotactic Ablative Radiation Therapy(SABR) of Lung Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.